The rise of Sildenafil initially drove a period of growth for pharma, nevertheless recent shifts present a murky scenario for shareholders. Lower-cost versions are reducing earnings, and persistent legal battles add https://karimznke697794.dailyblogzz.com/41666917/the-blue-pill-and-big-pharma-a-precarious-bet